|Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer|
MR Mirza, BJ Monk, J Herrstedt, AM Oza, S Mahner, A Redondo, ...
New England Journal of Medicine 375 (22), 2154-2164, 2016
|Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome|
RW Tothill, AV Tinker, J George, R Brown, SB Fox, S Lade, DS Johnson, ...
Clinical cancer research 14 (16), 5198-5208, 2008
|Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial|
EM Swisher, KK Lin, AM Oza, CL Scott, H Giordano, J Sun, GE Konecny, ...
The lancet oncology 18 (1), 75-87, 2017
|Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study|
W Sieh, M Köbel, TA Longacre, DD Bowtell, A DeFazio, MT Goodman, ...
The lancet oncology 14 (9), 853-862, 2013
|Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss|
B Clarke, AV Tinker, CH Lee, S Subramanian, M Van De Rijn, D Turbin, ...
Modern Pathology 22 (3), 393-402, 2009
|Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas|
D Etemadmoghadam, A Defazio, R Beroukhim, C Mermel, J George, ...
Clinical cancer research 15 (4), 1417-1427, 2009
|“Platinum resistant” ovarian cancer: what is it, who to treat and how to measure benefit?|
A Davis, AV Tinker, M Friedlander
Gynecologic oncology 133 (3), 624-631, 2014
|Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer|
CM Phelan, KB Kuchenbaecker, JP Tyrer, SP Kar, K Lawrenson, ...
Nature genetics 49 (5), 680-691, 2017
|Secondary somatic mutations restoring RAD51C and RAD51D associated with acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma|
O Kondrashova, M Nguyen, K Shield-Artin, AV Tinker, NNH Teng, ...
Cancer discovery 7 (9), 984-998, 2017
|Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas|
MS Anglesio, S Kommoss, MC Tolcher, B Clarke, L Galletta, H Porter, ...
The Journal of pathology 229 (1), 111-120, 2013
|Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers|
JS Kwon, A Tinker, G Pansegrau, J McAlpine, M Housty, M McCullum, ...
Obstetrics & Gynecology 121 (1), 14-24, 2013
|Clinical trials in recurrent ovarian cancer|
M Friedlander, E Trimble, A Tinker, D Alberts, E Avall-Lundqvist, M Brady, ...
International Journal of Gynecologic Cancer 21 (4), 2011
|Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated …|
AM Oza, AV Tinker, A Oaknin, R Shapira-Frommer, IA McNeish, ...
Gynecologic oncology 147 (2), 267-275, 2017
|The role of the fallopian tube in ovarian cancer|
AA Tone, S Salvador, SJ Finlayson, AV Tinker, JS Kwon, CH Lee, ...
Clin Adv Hematol Oncol 10 (5), 296-306, 2012
|Chemotherapy response score: development and validation of a system to quantify histopathologic response to neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma|
S Böhm, A Faruqi, I Said, M Lockley, E Brockbank, A Jeyarajah, ...
Journal of Clinical Oncology 33 (22), 2457-2463, 2015
|The challenges of gene expression microarrays for the study of human cancer|
AV Tinker, A Boussioutas, DDL Bowtell
Cancer cell 9 (5), 333-339, 2006
|Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors|
MS Anglesio, JM Arnold, J George, AV Tinker, R Tothill, N Waddell, ...
Molecular cancer research 6 (11), 1678-1690, 2008
|A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND. 184|
HJ Mackay, A Tinker, E Winquist, G Thomas, K Swenerton, A Oza, ...
Gynecologic oncology 116 (2), 163-167, 2010
|BRCA reversion mutations in circulating tumor DNA predict primary and acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma|
KK Lin, MI Harrell, AM Oza, A Oaknin, I Ray-Coquard, AV Tinker, ...
Cancer discovery 9 (2), 210-219, 2019
|Low-stage ovarian clear cell carcinoma: population-based outcomes in British Columbia, Canada, with evidence for a survival benefit as a result of irradiation|
PJ Hoskins, N Le, B Gilks, A Tinker, J Santos, F Wong, KD Swenerton
Journal of clinical oncology 30 (14), 1656-1662, 2012